← Back to patent-cliff list
CT-102
Tier C — Watch / tradeCT-102
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：IGF1R
Indications (approved)：Liver cancer, Hepatocellular carcinoma
Regional status
US
-
EU
-
China
Phase II
2022-05-10
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CT-102?
Approved indications include: Liver cancer, Hepatocellular carcinoma.
When does the CT-102 patent expire?
No public expiry year is available for CT-102 yet; this page updates once verified.
How do I get a quote for CT-102 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05